Also, eIND results can't be discounted as there is now objective, scientifically backed evidence leronlimab MOA works as intended. In my view, eIND is now just as powerful as the gold standard blinded placebo controlled studies. Now we have this, IN CONJUNCTION WITH, cd12 statistically significant primary endpoints met. Too powerful for the FDA to ignore. But that's assuming CYDY actually acknowledges the Dr. BP paper.